Impairment of Fibrinolysis and Vascular Disease

  • E. J. P. Brommer
  • P. Brakman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


Among the proteolytic enzymes capable of resolving fibrin deposits in the body, plasmin appears to be the most important. Leucocyte proteases probably contribute to the resolution of thrombi and fibrin-rich exudates, but as yet their relevance to the removal of fibrin is less clear than that of “classical” fibrinolysis. In this paper the relation between vascular disease and classical i.e. plasmin-mediated fibrinolysis will be examined.


Factor VIII Fibrinolytic Activity Fibrinolytic System Thrombotic Disease Fibrinolytic Capacity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aberg, M., Nilsson, I.M., Vilhardt, H. The release of fibrinolytic activator and factor VIII after injection of DDAVP. p. 92–97. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol.4, Eds.: Davidson, Cepezak, Samama, Desnoyers, Churchill Livingstone, 1979, Edimburgh/London/New York.Google Scholar
  2. Aoki, N., Moroi, M., Sakada, Y., Yoshida, N., & Matsuda, M.1978, Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J. Clin. Invest., 61: 1186–1195.PubMedCrossRefGoogle Scholar
  3. Astrup, T. Blood coagulation, fibrinolysis and the development of the thrombogenic theory of arteriosclerosis. In: Le role de la paroi artérielle dans 1’athérogénèse. 1976. Centre. Nat. Rech. Sc.Google Scholar
  4. Astrup, T., & Rosa, A.T. 1974. A plasminogen proactivator-activator system in human blood effective in absence of Hageman factor. Ihromb. Res. 4: 609–613.CrossRefGoogle Scholar
  5. Bagge, L., Carlin, G., Hjelmstedt, A., Hogstorp Jacobsson, H., Modig, J., Saldeen, T. 1979. Fibrinolysis inhibition after a standardized trauma, total hip replacement surgery. Thromb. Haemost. 42: 278 (abstract).Google Scholar
  6. Bernik, M.B. & Kwaan, H.C. 1971. Inhibitors of fibrinolysis in human tissues in culture. Am. J. Physiol. 221: 916.PubMedGoogle Scholar
  7. Brakman, p., Mohler, E.R. & Astrup, T. 1966. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis. Scand. J. Haematol. 3: 389–398.PubMedCrossRefGoogle Scholar
  8. Brakman, P. & Astrup, T. Selective inhibition of tissue plasminogen activator in thrombotic disease. In: Abstract volume XIII Intern. Congr. Haemat. Munich, p.173. (1970).Google Scholar
  9. Cash, J. 1968. A new approach to studies of the fibrinolytic enzyme system in man. Am. Heart J. 75: 424–427.PubMedCrossRefGoogle Scholar
  10. Collen, D. 1980. On the regulation and control of fibrinolysis. Thromb. & Haemost. 43: 77–89.Google Scholar
  11. Duguid, J.B. 1949. Pathogenesis of arteriosclerosis. Lancet 2: 925.PubMedCrossRefGoogle Scholar
  12. Epstein, S.E., Rosing, D.R., Brakman, P., Redwood, D.R., Astrup, T. 1970. Impaired fibrinolytic response in patients with type IV hyperlipoproteinemia. Lancet 2: 631–634.PubMedCrossRefGoogle Scholar
  13. Fearnley, G.R. 1953. Fibrinolysis by adsorption. Nature (London) 172: 544.CrossRefGoogle Scholar
  14. Gritsyuk, A.I. & Schigelsky, V.I. 1979. Evaluation of blood coagulation and prethrombotic state in patients with coronary atherosclerosis by application of controlled local venous blokade. Circ. 60: 220A.Google Scholar
  15. Haverkate, F. & Brakman, P. In: Progress in chemical fibrinolysis and thrombolysis. Eds.: Davidson, J.F., Samama, M.M. & Desnoyers, P.C. Raven Press NY, 1975, p.151. Fibrin Plate assay.Google Scholar
  16. Hender, U. 1973. Studies on an inhibitor of plasminogen activator in human serum. Thromb. Diath. Haemorrh. 30: 414–424.Google Scholar
  17. Hender, U. & Nilsson, I.M. Acquired anticoagulants against factors XI and XII in patients with severe thrombotic disease, In: XVI Intern. Cong. Haematol. Kyoto. Sept. 1976 Abstract 8–88, p. 341.Google Scholar
  18. Hisazumi, H., Naoito, K., Misaki, T., Kosaka, S. 1974. Urokinase inhibitor in patients with bladder cancer. Urological Research 2: 137–142.PubMedCrossRefGoogle Scholar
  19. Inglesby, T.V., Singer, J.W., Gordon, D.S. 1973. Abnormal fibrinolysis in familial pulmonary hypertension. Am. J. Med. 55: 5–14.PubMedCrossRefGoogle Scholar
  20. Isacson, S. & Nilsson, I.M. 1972. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir. Scand. 138: 313.PubMedGoogle Scholar
  21. Johansson, L., Hender, U., Nilsson, I.M. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med. Scand. 203: 477–480.Google Scholar
  22. Kawano, T., Morimoto, K. & Vemura, Y. 1968. Urokinase inhibitor in human placenta. Nature 217: 253.PubMedCrossRefGoogle Scholar
  23. Kluft, C. 1978. Levels of plasminogen activators in human plasma: new methods to study the intrinsic and extrinsic activators. In; Progress in chemical fibrinolysis and thrombolysis, Vol.3. Eds.: Davidson, Rowan, Samama & Desnoyers. Raven Press NY, p. 141–154.Google Scholar
  24. Kluft, C. 1979. Studies on the fibrinolytic system in human plasma: Quantitative determination of plasminogen activators and proactivators. Thrombos. Haemostas. 41: 365–383.Google Scholar
  25. Ludlam, C.A., Peake, I.R., Allen, N., Davies, B.L., Furlong, R.A., Bloom, A.L. 1980. Factor VIII and fibrinolytic response to deamino-8-D-arginine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand’s disease. Brit. J. Haemat. 45:499–511.PubMedCrossRefGoogle Scholar
  26. Meade, T.W., North, W.R.S., Chakrabarti, S., Stirling, Y., Haines, A.P., Thompson, S.G., Brozović, M. 1980. Haemostatic function and cardiovascular death; early results of a prospective study. Lancet 1: 1050–1054.PubMedCrossRefGoogle Scholar
  27. Nilsson, I.M., Holmberg, L., Aberg, M., Vilhardt, H. 1980. The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand’s disease. Scan. J. Haematol. 24: 351–359.CrossRefGoogle Scholar
  28. Nolf, P. 1908. Contribution à l’étude de la coagulation du sang. La fibrinolyse. Arch. Int Physio1. 6: 306–359.Google Scholar
  29. Peabody, R.A., Tsapogas, M.J., Kwang-Tzen, W. 1974. Altered endogenous fibrinolysis and biochemical factors in atherosclerosis. Arch. Surg. 109: 309.PubMedCrossRefGoogle Scholar
  30. Ratnoff, O.D., Busse, R.J. & Sheon, R.P. 1968. The demise of John Hageman. N. Engl. J. Med. 279: 760.CrossRefGoogle Scholar
  31. Rosing, D.R., Redwood, D.R., Brakman, P., Astrup, T. & Epstein, S.E. 1973. Impairment of the diurnal fibrinolytic response in man. Effects of aging, type IV hyperlipoproteinemia, and coronary heart disease. Circ. Res. 32: 752–758.PubMedCrossRefGoogle Scholar
  32. Rijken, D.C. 1980. Thesis Leiden. Plasminogen activator from human tissue.Google Scholar
  33. Rijken, D.C., Wijngaards, G., Welbergen, J. 1980. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb. Res. 18: 815–830.Google Scholar
  34. Robbins, K.C., Wohl, R.C., Summaria, L. 1979. Variant plasminogens in patients with history of venous thrombosis. Thromb. Haemost. 42: 190. Abstract London.Google Scholar
  35. Rokitansky, K. von. Uber einige der wichtigsten Krankheiten der Arterien. Meidingen, Vienna, 1852.Google Scholar
  36. Saldeen, T. 1976. The microembolic syndrome. Microvasc. Res. 11: 227.PubMedCrossRefGoogle Scholar
  37. Thorsen, S., Glas-Greenwalt, P. & Astrup, T. 1972. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb. Diath. Haemorrh. 28: 65–74.PubMedGoogle Scholar
  38. Thorsen, S. 1975. Differences in the binding to fibrin of native plasminogen modified by proteolytic degradation. Biochim. Biophys. Acta 393: 55–65.PubMedCrossRefGoogle Scholar
  39. Uszynski, M. & Abildgaard, U. 1971. Separation and characterization of two fibrinolytic inhibitors from human placenta. Thromb. Diath. Haemorrh. 25: 580.PubMedGoogle Scholar
  40. Williams, R.S., Logue, E.E., Lewis, J.J., Barton, T., Stead, N. W., Wallace, A.G. & Pizzo, S.V. 1980. Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N. Engl. J. Med. 303: 987–991.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • E. J. P. Brommer
    • 1
  • P. Brakman
    • 1
  1. 1.Gaubius Institute TNOLeidenThe Netherlands

Personalised recommendations